PEGBIO CO-B: Recommends granting exclusive licensing of VISEPEGENATIDE (PB-119) in the Middle East and Africa

According to the announcement from Zhitong Finance APP, PEGBIO CO-B (02565) is pleased to announce that it has entered into a non-binding term sheet with PDC FZ-LLC in the United Arab Emirates regarding the exclusive license for the company's product Visepegenatide (PB-119) (a subcutaneous GLP-1 receptor agonist for the treatment of type 2 diabetes and weight management). Under the proposed terms, PDC will be granted an exclusive license to develop, distribute, market, and commercialize the product in the Middle East and Africa. This collaboration represents an important milestone in the global commercialization strategy for the company's PB-119. The license covers regional development, product registration, local production involving comprehensive technology transfer, and exclusive rights for full commercialization. The product will be sold in the region under a trademark owned by PDC. This partnership is of significant strategic importance, as PDC's extensive regional expertise and infrastructure can accelerate market access and penetration, validate the company's asset output strategy, and make a substantial contribution to the global layout of the product and the company's long-term value creation. The Middle East and Africa represent a large and continuously growing market for diabetes and obesity treatment drugs. The high prevalence and rising trend of these diseases highlight the significant unmet medical needs and commercial potential for innovative therapies like PB-119. PDC is a leading pharmaceutical R&D organization in the Middle East and Africa, with an excellent track record in conducting clinical trials. The PDC-CRO group provides end-to-end innovative solutions for Phase I to IV clinical trials, real-world evidence studies, and life sciences solutions (health economics and outcomes research and consulting) throughout the region. Its established leadership position and deep regional integration are further strengthened by a wide network of clinical trial sites and close collaboration with key opinion leaders, resulting in significant medical impact. This makes PDC one of the most suitable partners for accelerating the market access and commercialization process of innovative Chinese drugs (such as PB-119) in the region. As of the date of this announcement, PDC is independent of the company and its related parties and has no connections with them. The company's board of directors believes that PDC's decision to engage in this collaboration as a respected regional leader strongly validates the company's proprietary R&D capabilities, the outstanding clinical characteristics of Visepegenatide (PB-119), and its enormous market potential. This collaboration highlights the international competitiveness and value of the company's product pipeline, reinforcing the company's position as an innovator in the field of metabolic diseases. The proposed collaboration with PDC is an important step in expanding the global layout of PB-119 and aligns with the overall interests of the company and its shareholders